Advances in GLP-1 treatment: focus on oral semaglutide
DNA ,
The scenario where adding phentermine makes the strongest case is this: a patient on maximum tirzepatide dosing for at least 6 months, with a documented weight loss plateau lasting 8 or more weeks, who has optimized diet, exercise, sleep, and stress management, and whose provider has ruled out medical causes for the plateau (thyroid dysfunction, medication interactions, fluid retention)
Milliman's experts have diverse actuarial, operational, and market experience from decades in the realm of government healthcare services
Employer Considerations As the 2024 open enrollment season approaches, employers have several considerations before them: Exclude coverage: Employers might see lower drug costs and restrain any increase in member premiums by excluding the coverage of GLP-1 drugs approved for weight loss